An observational study in Chronic Obstructive Pulmonary Disease, sponsored by Boehringer Ingelheim. Completed at 177 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-28.
Sponsored by Boehringer Ingelheim · Observational
This observational non-interventional study is designed to demonstrate the improvement of physical function in COPD patients with exercise-induced dyspnoea on treatment with Spiriva (tiotropium 18 µg capsules) and allows adverse events to be recorded and evaluated.
Study Design:
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 1,296 is above the median of 157 across 929 observational studies indexed under Lung Diseases.
Browse Lung Diseases studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
patients of office-based pulmonology practices
Men or women with COPD and a thoracic gas volume (TGV) of \< 140% at rest, MRC value of 2 or more.
Exclusion Criteria:
The primary endpoint was the proportion of patients with an improvement by ≥10 points in the standardised PF-10 score after 6 weeks of treatment with Spiriva® 18 Microgram
Time frame: 6 weeks
The secondary endpoint was the change in the standardised PF-10 score within 6 weeks of treatment with Spiriva® 18 Microgram
Time frame: 6 weeks
Showing the first 100 of 177 sites.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim